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Microbiological efficacy of lomefloxacin and other drugs
regarding microorganisms isolated from the human conjunctiva
Purpose: To evaluate and compare the  in vitro susceptibility of human
conjunctival bacterial isolates to various antimicrobial agents, including
lomefloxacin, other fluoroquinolones (ciprofloxacin, norfloxacin, and
ofloxacin), aminoglycosides (gentamicin, tobramycin, and amicacin),
and cephalosporin (cephalothin). Methods: Antibiotic susceptibility
tests conducted over a period of 27 months with 613 bacterial isolates
from the conjunctiva were retrospectively analyzed. Results: In relation
to the total number of positive isolates, the fluoroquinolones showed
greater  in vitro effectiveness than the other analyzed antibiotics. All
bacterial isolates showed significantly higher susceptibility to cipro-
floxacin than to lomefloxacin. Conclusion: The fluoroquinolones are not
only equally effective against all conjunctival bacterial isolates, but they
also show superior antimicrobial activity in comparison to amino-
glycosides and cephalothin. These results suggest that fluoroquinolones,
such as lomefloxacin, can be beneficially prescribed for conjunctival
infections and also as prophylaxis in ocular surgery.
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INTRODUCTION
The most frequent infections of the conjunctiva which are submitted to
laboratory evaluation are due to bacteria, and an initial treatment with broad-
spectrum antibiotics is usually recommended after the clinical diagnosis and
after scraping the site of infection(1-3). Susceptibility tests for microorganisms
isolated from ocular infections are recommended, since the results are useful
not only in specific cases but also as epidemiological data(4-5).
The fluoroquinolones have been available in the United States of
America since 1962. Lomefloxacin is a third-generation fluoroquinolone
available in Brazil for systemic administration since 1993. Lomefloxacin is
nearly completely absorbed when taken orally and is slowly eliminated,
having a half-life of seven to eight hours(6). Similar to other fluoroquinolo-
nes, lomefloxacin has a broad spectrum of action, including Gram-positive
and -negative microorganisms. As a third-generation quinolone, it also has
the advantage of being effective against some anaerobic bacteria(1-2, 7-10).
The antibacterial activity of fluoroquinolones, such as lomefloxacin, is
mediated through inhibition of the bacterial enzyme DNA gyrase, resulting
in failure to synthesize bacterial DNA. As a consequence, fluoroquino-
lones are bactericidal(1, 9, 11).
Arq Bras Oftalmol 2001;64:147-51
148   Microbiological efficacy of lomefloxacin and other drugs regarding microorganisms isolated from the human conjunctiva
Topical instillation of lomefloxacin, as compared to other
quinolones, achieved better intraocular penetration, leading
to higher concentrations in the aqueous humor(10, 12-13). The
manufacturer suggested twice a day topical use of lomeflo-
xacin. Its liposolubility facilitates its storage in the goblet cells
of the conjunctiva, providing bioavailability throughout the
day(6). Several studies have already demonstrated the efficacy
of fluoroquinolones, used separately or in combination with
other antibiotics, in the treatment of ocular infections of the
conjunctiva or cornea(1-3, 11, 14-17).
The purpose of this study was to evaluate the in vitro
susceptibility to lomefloxacin of microorganisms of the con-
junctiva, isolated by the Ocular Microbiology Laboratory of
the Federal University of São Paulo (UNIFESP-EPM), and also
to compare lomefloxacin, in terms of effectiveness, with other
fluoroquinolones (ciprofloxacin, norfloxacin, and ofloxacin),
with aminoglycosides (amicacin, gentamicin, and tobramy-
cin), and with a cephalosporin (cephalothin).
METHODS
The materials analyzed in this study were collected from
patients treated at the São Paulo Hospital and also in the
community. The samples for microbiological evaluation were
obtained directly from the infected area in all cases of
conjunctival infections. Sterile cotton swabs soaked in Brain-
Heart-Infusion solution were used for collection of samples
for cultures(18-19).
All the materials were inoculated onto sheep blood agar,
chocolate agar, and Sabouraud dextrose agar(5, 20). Microsco-
pic evaluation of conjunctival smears by Gram stain and
Giemsa stain was also included as part of the standard con-
junctival scraping protocol, in order to assess the bacterial
and cellular populations, respectively(21). Cultures were consi-
dered positive when presenting a significant growth of at least
two seeded samples in one or more plates.
Antibiotic susceptibility was determined for all positive
cultures using the Kirby-Bauer disc diffusion method(4, 21-22),
with the antibiotic concentration in the disc individually
determined for each antibiotic (Table 1)(4). The reading was
performed by measuring the diameter of the growth inhibiting
zone around the disk(4), in agreement with the National
Committee for Clinical Laboratory Standards (NCCLS) criteria
for all antibiotics, with one of three resulting grades: resistant,
intermediately sensitive, or susceptible (Table 1)(4-5, 23).
Laboratory test results of cases referred to the Ocular
Microbiology Laboratory of the UNIFESP-EPM between
November 1997 and February 2000 were retrospectively
analyzed. Of the 2030 cases examined by the laboratory during
the 27 months, a total of 1642 were diagnosed as conjunc-
tivitis. Cultures were carried out and considered positive if
showing growth of one or more microorganisms. This study
was based on 613 positive bacterial isolates that were submit-
ted to antibiotic susceptibility tests.
In order to simplify analysis of the results of this study,
strains were grouped as follows: coagulase-negative Staphy-
lococcus (CNS); Staphylococcus aureus (S. aureus); Haemo-
philus sp (Haem); other Gram-positive cocci (CGP) such as
Streptococcus pneumoniae, non-hemolytic Streptococcus,
Streptococcus sp, and Streptococcus viridians; Gram-
negative microorganisms (Gram Neg) such as Proteus mira-
bilis, Proteus penneri, Serratia sp, and Neisseria sp; other
Gram-positive microorganisms (Gram Pos) such as C. xerosis;
Moraxella sp (Morax); and Pseudomonas sp (Pseudo)(19).
Statistical analysis using the chi-square test was applied
to one sample, assuming that the collection site did not bias
the measured frequencies(24-25). In order to verify the diffe-
rences between the proportions of microorganisms suscep-
tible to lomefloxacin and ciprofloxacin, a test for two propor-
tions, whose populations were not independent, was used as
proposed by McNemar. The statistical result calculated was
defined as Uo
2 (18). The level of significance was 0.05 (5%).
RESULTS
A total of 613 bacterial isolates was examined in this study.
Gram-positive cocci accounted for 539 (87.9%) of all bacterial iso-
lates, being further classified as CNS in 390 (63.6%) of the cases
and as S. aureus in 116 (18.9%) of the positive isolates. As for
Gram-negative microorganisms, Haemophilus sp was the most
frequently isolated (6.5% of total bacterial isolates) (Table 2).
Susceptibility to lomefloxacin was shown 98.5% of all
bacterial isolates, including 99.5% of CNS and 99.1% of S.
aureus. Almost all Gram-negative microorganisms were sus-
ceptible to lomefloxacin at a level of 93.3-100%, except for
Pseudomonas sp, which was susceptible in only two out of
four isolates (Table 2).
Of the 613 microbial isolates, 587 (95.8%) were susceptible
to cephalothin. Among the aminoglycosides, amicacin was
associated with the highest level of susceptibility (95.6%), but
this antibiotic is not commercially available. The two drugs
available for topical use, gentamicin and tobramycin, were
associated with susceptibilities of around 91% (Table 2).
Table 1. Grading of antibiotic susceptibility by the disk diffusion
method, according to the NCCLS criteria for different antibiotics
(2000 - São Paulo, Brazil)
Disk Diameter of the inhibiting
Antibiotic content zone around the disk (mm)
(µg) Resistant Intermediate Susceptible
Gentamicin 10 ≤12 13 - 14 ≥15
Amicacin 30 ≤14 15 - 16 ≥17
Tobramycin 10 ≤12 13 - 14 ≥15
Cephalothin 30 ≤14 15 - 17 ≥18
Lomefloxacin 10 ≤18 19 - 21 ≥22
Ciprofloxacin 5 ≤15 16 - 20 ≥21
Norfloxacin 10 ≤12 13 - 16 ≥17
Ofloxacin 5 ≤12 13 - 15 ≥16
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The overall susceptibility of the bacterial isolates to the
quinolones, including lomefloxacin, the newer quinolone, is at
a level greater than 98.5%. Ciprofloxacin had the broadest
activity, with 610 isolates (99.5%) being sensitive (Table 3).
Ciprofloxacin was associated with significantly more instan-
ces of susceptibility than was lomefloxacin (Table 4).
CONCLUSIONS
Many ophthalmologists start treatment of external ocular
infections before the causative microorganisms have been
identified or submitted to antibiotic susceptibility tests.
Consequently, broad-spectrum antibiotics are routinely used
in the treatment of ocular infections(4, 23, 26).
Although the majority of cases of bacterial conjunctivitis
are presumably self-limited, without the need for medical
intervention, studies have demonstrated that antibiotic
therapy hastens the eradication of bacteria, prevents the
dissemination of the infection to other structures, decreases
the risk of systemic disease, and shortens the symptomatic
period, allowing the patient to return more quickly to his/her
normal activities(1, 3-4, 23, 26).
As in previous studies, many of our cultures showed no
microbial growth. There are several possible explanations for
this finding, including insufficient material, the use of topical
antibiotics before cultures could be inoculated, viral etiology,
or the presence of microorganisms that do not grow in regular
media, such as anaerobic bacteria or Mycobacteria(19-20, 31).
Some antimicrobial drugs are subject to restricted use. For
instance, cephalothin is highly effective against Gram-posi-
tive cocci, but can be obtained only in specially formulated
prescriptions and in cases of demonstrated need. Its circums-
cribed use is intended to prevent the development of resistant
strains.
According to several studies, the development of resis-
tance of ocular bacteria to many aminoglycosides has limited
Table 2. Antibiotic susceptibility of conjunctival bacterial isolates to lomefloxacin, aminoglycosides and cephalothin
(2000 - São Paulo, Brazil)
                   Antibiotics
Bacteria N                 Lomefloxacin                    Amicacin                 Gentamicin                  Tobramycin                   Cephalothin
N % N % N % N % N %
CNS 390 388 99.5 390 100 356 91.3 364 93.3 387 99.2
S. aureus 116 115 99.1 116 100 111 95.7 110 94.8 110 94.8
Haem 40 40 100 35 87.5 36 90.0 38 95.0 39 97.5
CGP 33 30 90.9 13 39.4 22 66.7 17 51.5 32 97.0
Gram Neg 15 14 93.3 15 100 15 100 15 100 10 66.7
Morax 10 10 100 8 80.0 10 100 10 100 4 40.0
Gram Pos 5 5 100 5 100 5 100 5 100 5 100
Pseudo 4 2 50.0 4 100 4 100 4 100 0 0
TOTAL 613 604 98.5 586 95.6 559 91.2 563 91.8 587 98.5
CNS - coagulase-negative Staphylococcus; S. aureus - Staphylococcus  aureus; Haem - Haemophilus  sp; CGP - other Gram positive cocci (Streptococcus pneumoniae,
non-hemolytic  Streptococcus, Streptococcus  sp and Streptococcus viridans); Gram Neg - Gram negative microorganisms (Proteus mirabilis, Proteus penneri, Serratia
sp and Neisseria sp); Morax - Moraxella sp; Gram Pos - Gram positive microorganisms (C. xerosis); Pseudo - Pseudomonas sp
Table 3. Antibiotic susceptibility of conjunctival bacterial isolates to fluoroquinolones (2000 - São Paulo, Brazil)
Antibiotics
Bacteria N                    Lomefloxacin                    Ciprofloxacin                        Norfloxacin                           Ofloxacin
N % N % N % N %
CNS 390 388 99.5 388 99.5 388 99.5 388 99.5
S. aureus 116 115 99.1 115 99.1 115 99.1 115 99.1
Haem 40 40 100 40 100 40 100 40 100
CGP 33 30 90.9 33 100 33 100 32 97.0
Gram Neg 15 14 93.3 15 100 14 93.3 14 93.3
Morax 10 10 100 10 100 10 100 10 100
Gram Pos 5 5 100 5 100 5 100 5 100
Pseudo 4 2 50.0 4 100 4 100 2 50.0
TOTAL 613 604 98.5 610 99.5 609 99.3 606 98.9
CNS - coagulase-negative Staphylococcus; S. aureus - Staphylococcus aureus; Haem - Haemophilus sp; CGP - other Gram positive cocci (Streptococcus pneumoniae,
non-hemolytic Streptococcus, Streptococcus sp and Streptococcus viridans); Gram Neg - Gram negative microorganisms (Proteus mirabilis, Proteus penneri, Serratia
sp and Neisseria sp); Morax - Moraxella sp; Gram Pos - Gram positive microorganisms (C. xerosis); Pseudo - Pseudomonas  sp
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their usefulness. The mechanism of action of the fluoroquino-
lones helps to account for the low incidence of resistant
microorganisms(1, 3). The fluoroquinolones have a broad
spectrum of action(1-3, 21), and are stable drugs as marketed in
the form of eye drops at a concentration of 3 mg/ml(1). It is
known that the susceptibility of anaerobic bacteria is greater
to third-generation quinolones, such as lomefloxacin. As
anaerobic bacteria were not assessed in this study, we could
not verify these findings(9).
While other studies have demonstrated the susceptibi-
lity of Gram-positive and Gram-negative bacteria to quino-
lones(1-3, 14, 26, 32), stocks of CNS and S. aureus resistant to
quinolones were described by the same laboratory that
discovered an increasing number of strains of Gram-positi-
ve cocci resistant to prescribed topical antibiotics(21, 33-34).
The use of an antibiotic as a prophylactic drug prior to
ocular surgery has the objective of eliminating most, if not all,
microorganisms present in the conjunctiva. In this way, the
risk of infection during surgery and in the immediate post-
operative period, when the surgical wound is not yet closed,
can be minimized. It is of particular concern that the
prophylactic topical antibiotic used should be able to reach its
minimal inhibitory concentration in the anterior chamber or
vitreous.
Basic research on lomefloxacin, to evaluate its in vitro
effectiveness, its speed of action, its concentration at the site
of infection, and its half-life, is being performed to guarantee
satisfaction of the minimum requirements for drugs intended
for ophthalmic use(7, 9-10, 12). In vitro susceptibilities of isolated
ocular microorganisms do not always translate into in vivo
efficacy of particular drugs, but they are nonetheless strong
epidemiological and therapeutic indicators(4, 27 -28). In conclu-
sion, we recommend prescribing lomefloxacin and other qui-
nolones(1-3, 14, 26-27, 32, 34) for the treatment of conjunctival in-
fections and for prophylaxis in ocular surgery.
RESUMO
Objetivo: Avaliar e comparar a atividade biocida in vitro de
bactérias isoladas da conjuntiva humana à lomefloxacina, a
outras fluorquinolonas (ciprofloxacina, norfloxacina e ofloxa-
cina), aos aminoglicosídeos (gentamicina, tobramicina e
amicacina) e à cefalosporina (cefalotina). Métodos: Foram
analisados retrospectivamente os resultados dos antibio-
gramas realizados no período de 27 meses com 613 bactérias
isoladas da conjuntiva. Resultados: A eficácia in vitro das
quinolonas de acordo com o total dos isolamentos positivos
foi superior em relação aos outros antibióticos avaliados. A
suscetibilidade do total de bactérias à ciprofloxacina foi
significantemente mais alta quando comparada à lomeflo-
xacina. Conclusão: Os resultados praticamente equivalentes
da suscetibilidade de bactérias isoladas da conjuntiva a
fluorquinolonas, associado à maior eficácia deste grupo de
antimicrobianos em relação aos aminoglicosídeos e à cefa-
lotina, representam uma possibilidade de prescrição de
quinolonas, como lomefloxacina, no tratamento de infecções
conjuntivais, além do possível uso profilático em cirurgias
oculares.
Descritores: Quinolonas/uso terapêutico; Fluoroquinolo-
na/farmacologia; Doenças da conjuntiva/terapia; Doenças
da conjuntiva/microbiologia
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